seqHPV NGS Genotyping

Introduction

Identification of Human papilloma virus (HPV) infection is an important tool for screening and prevention of carcinoma of the cervix, as nearly all of cervical cancer cases (99.7%) worldwide are associated with HPV infection.

seqHPV™ HPV Genotyping Test combines self-sampling technology and NGS-based genotyping assay to accurately detect various HPV genotypes from both high-risk and low-risk group, serve as the primary screening test for cervical cancer.

Advantage

Full Coverage of High-Risk HPV Associated with Cervical Cancer
Screening test covering all high-risk HPV genotypes associated with cervical cancer as per recommended by World Health Organization
Flexible Sampling Methods
Applicable for both professional physician-sampling and self-sampling method with similar outcome.
Diversified Sample Preservation Methods
Test compatible with wet and dry swab specimen
High throughput
Ideal for screening program by tested up to 6000 samples on validate platforms at low cost
Flexible applications for clinical and research purpose

Screens for

14 high risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 2 low risk HPV genotypes 6 and 11.

Sample requirement

Cervical exfoliated cell (prepared on DNA storage card or preservation fluid)

seqHPV NGS Genotyping

COMPANY